Kristiana Grigoriadis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristiana Grigoriadis has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Charles Swanton
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
30 shared publications - Emma Colliver
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
28 shared publications - Nicholas McGranahan
Cancer Research UK Lung Cancer Centre of Excellence University College London Cancer Institute London UK
28 shared publications - Takahiro Karasaki
Department of Thoracic Surgery, Respiratory Center, Toranomon Hospital, Tokyo, JPN
28 shared publications - Allan Hackshaw
Cancer Research UK & UCL Cancer Trials Centre, UCL, London, UK
27 shared publications - Mariam Jamal-Hanjani
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute
27 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by Springer Nature in Nature
- Vol. 646 (8083) , 190-197
Clone copy number diversity is linked to survival in lung cancer
Both single nucleotide variants (SNVs) and somatic copy number alterations (SCNAs) accumulate in cancer cells during tumour development, fuelling clonal evolution. However, accurate estimation of clone-specific copy numbers from bulk DNA-sequencing data is challenging. Here we present allele-specific phylogenetic analysis of copy number alterations (ALPACA), a method to infer SNV and SCNA coevolution by leveraging phylogenetic trees reconstructed from multi-sample bulk tumour sequencing data using SNV frequencies. ALPACA estimates the SCNA evolution of simulated tumours with a higher accuracy than current state-of-the-art methods1–4. ALPACA uncovers loss-of-heterozygosity and amplification events in minor clones that may be missed using standard approaches and reveals the temporal order of somatic alterations. Analysing clone-specific copy numbers in TRACERx421 lung tumours5,6, we find evidence of increased chromosomal instability in metastasis-seeding clones and enrichment for losses affecting tumour suppressor genes and amplification affecting CCND1. Furthermore, we identify increased SCNA rates in both tumours with polyclonal metastatic dissemination and tumours with extrathoracic metastases, and an association between higher clone copy number diversity and reduced disease-free survival in patients with lung cancer.
- 13 August 2025
- Published by Springer Nature in Nature
- Vol. 646 (8083) , 190-197
Open AccessClone copy number diversity is linked to survival in lung cancer
Both single nucleotide variants (SNVs) and somatic copy number alterations (SCNAs) accumulate in cancer cells during tumour development, fuelling clonal evolution. However, accurate estimation of clone-specific copy numbers from bulk DNA-sequencing data is challenging. Here we present allele-specific phylogenetic analysis of copy number alterations (ALPACA), a method to infer SNV and SCNA coevolution by leveraging phylogenetic trees reconstructed from multi-sample bulk tumour sequencing data using SNV frequencies. ALPACA estimates the SCNA evolution of simulated tumours with a higher accuracy than current state-of-the-art methods1–4. ALPACA uncovers loss-of-heterozygosity and amplification events in minor clones that may be missed using standard approaches and reveals the temporal order of somatic alterations. Analysing clone-specific copy numbers in TRACERx421 lung tumours5,6, we find evidence of increased chromosomal instability in metastasis-seeding clones and enrichment for losses affecting tumour suppressor genes and amplification affecting CCND1. Furthermore, we identify increased SCNA rates in both tumours with polyclonal metastatic dissemination and tumours with extrathoracic metastases, and an association between higher clone copy number diversity and reduced disease-free survival in patients with lung cancer.
- Top Cited PapersOpen Access
- 13 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 70-76
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a whole-genome-based, tumor-informed platform that has been analytically validated for ultrasensitive ctDNA detection at 1–3 ppm of ctDNA with 99.9% specificity. Through an analysis of 171 patients with early-stage lung cancer from the TRACERx study, we detected ctDNA pre-operatively within 81% of patients with lung adenocarcinoma (LUAD), including 53% of those with pathological TNM (pTNM) stage I disease. ctDNA predicted worse clinical outcome, and patients with LUAD with <80 ppm preoperative ctDNA levels (the 95% limit of detection of a ctDNA detection approach previously published in TRACERx) experienced reduced overall survival compared with ctDNA-negative patients with LUAD. Although prospective studies are needed to confirm the clinical utility of the assay, these data show that our approach has the potential to improve disease stratification in early-stage LUADs.
- 13 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 70-76
Top Cited PapersOpen AccessUltrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a whole-genome-based, tumor-informed platform that has been analytically validated for ultrasensitive ctDNA detection at 1–3 ppm of ctDNA with 99.9% specificity. Through an analysis of 171 patients with early-stage lung cancer from the TRACERx study, we detected ctDNA pre-operatively within 81% of patients with lung adenocarcinoma (LUAD), including 53% of those with pathological TNM (pTNM) stage I disease. ctDNA predicted worse clinical outcome, and patients with LUAD with <80 ppm preoperative ctDNA levels (the 95% limit of detection of a ctDNA detection approach previously published in TRACERx) experienced reduced overall survival compared with ctDNA-negative patients with LUAD. Although prospective studies are needed to confirm the clinical utility of the assay, these data show that our approach has the potential to improve disease stratification in early-stage LUADs.
- Open Access
- 9 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (1) , 86-101
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Human tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to sample this diversity, but cancer biomarkers may be confounded by spatiogenomic heterogeneity within individual tumors. Here we investigate clonally expressed genes as a solution to the sampling bias problem by analyzing multiregion whole-exome and RNA sequencing data for 450 tumor regions from 184 patients with lung adenocarcinoma in the TRACERx study. We prospectively validate the survival association of a clonal expression biomarker, Outcome Risk Associated Clonal Lung Expression (ORACLE), in combination with clinicopathological risk factors, and in stage I disease. We expand our mechanistic understanding, discovering that clonal transcriptional signals are detectable before tissue invasion, act as a molecular fingerprint for lethal metastatic clones and predict chemotherapy sensitivity. Lastly, we find that ORACLE summarizes the prognostic information encoded by genetic evolutionary measures, including chromosomal instability, as a concise 23-transcript assay.
- 9 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (1) , 86-101
Open AccessProspective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Human tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to sample this diversity, but cancer biomarkers may be confounded by spatiogenomic heterogeneity within individual tumors. Here we investigate clonally expressed genes as a solution to the sampling bias problem by analyzing multiregion whole-exome and RNA sequencing data for 450 tumor regions from 184 patients with lung adenocarcinoma in the TRACERx study. We prospectively validate the survival association of a clonal expression biomarker, Outcome Risk Associated Clonal Lung Expression (ORACLE), in combination with clinicopathological risk factors, and in stage I disease. We expand our mechanistic understanding, discovering that clonal transcriptional signals are detectable before tissue invasion, act as a molecular fingerprint for lethal metastatic clones and predict chemotherapy sensitivity. Lastly, we find that ORACLE summarizes the prognostic information encoded by genetic evolutionary measures, including chromosomal instability, as a concise 23-transcript assay.
- Open Access
- 4 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E15
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
- 4 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E15
Open AccessAuthor Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
TRACERx Consortium Members from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
All consortium members and their affiliations.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTRACERx Consortium Members from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
All consortium members and their affiliations.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Figure 5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil-rich TMEs are associated with activating mutations in PI3K and tumor-intrinsic CXCL8 upregulation. A, Representative crops of tumor-level H&E images with low TAN scores in the tumor nest and stroma (left) and high TAN scores in the tumor nest and stroma (right), inferred as the proportion of the neutrophil area in tumor/stroma from the total tumor/stroma tissue area. Scale bar, 50 μm; 400× magnification. B, Neutrophil cell density as defined by IMC compared between region-level TAN-low versus TAN-high tumor cores based on H&E scores in LUAD and LUSC. C and D, Proportion of tumor cores with (mut) and without (wt) PIK3CA driver mutations compared between TS:Neutrophil high versus other TME classes combined (C) and region-level TAN-High versus TAN-Low cores (D) in LUSC. P values were derived from a Chi-square test. E, Neutrophil cell density by PIK3CA mutation status, points colored by TME class assignment. F and G, TMM expression values for CXCL8 compared by PIK3CA mutation status (F) and between TME classes (G) in LUSC. H, Immunofluorescence images of CXCL8 RNAscope multiplexed with antibody staining of pancytokeratin (panCK) or MPO in an LUSC tumor region with a TS:Neutrophil high TME and subclonal PIK3CA mutation, and an LUSC patient with multiple TAN-high tumor regions and a clonal PIK3CA mutation. panCK and MPO examples for CRUK0075:R2 illustrate the same region of interest, whereas different regions of interest are shown for CRUK0468:R6. Scale bar, 100 μm. P values for B and E were calculated in a linear mixed-effects model with patient as the random-effect covariate. P values in F and G were derived from a limma–voom differential expression analysis correcting for multiple regions per tumor. ·, P < 0.1; *, P < 0.05; **, P < 0.01; ***, P < 0.001; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TMM, trimmed mean of M-values; TS, tumor/stroma; TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; TAN, tumor-associated neutrophils; H&E, hematoxylin and eosin; mt, mutant; wt, wild-type.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil-rich TMEs are associated with activating mutations in PI3K and tumor-intrinsic CXCL8 upregulation. A, Representative crops of tumor-level H&E images with low TAN scores in the tumor nest and stroma (left) and high TAN scores in the tumor nest and stroma (right), inferred as the proportion of the neutrophil area in tumor/stroma from the total tumor/stroma tissue area. Scale bar, 50 μm; 400× magnification. B, Neutrophil cell density as defined by IMC compared between region-level TAN-low versus TAN-high tumor cores based on H&E scores in LUAD and LUSC. C and D, Proportion of tumor cores with (mut) and without (wt) PIK3CA driver mutations compared between TS:Neutrophil high versus other TME classes combined (C) and region-level TAN-High versus TAN-Low cores (D) in LUSC. P values were derived from a Chi-square test. E, Neutrophil cell density by PIK3CA mutation status, points colored by TME class assignment. F and G, TMM expression values for CXCL8 compared by PIK3CA mutation status (F) and between TME classes (G) in LUSC. H, Immunofluorescence images of CXCL8 RNAscope multiplexed with antibody staining of pancytokeratin (panCK) or MPO in an LUSC tumor region with a TS:Neutrophil high TME and subclonal PIK3CA mutation, and an LUSC patient with multiple TAN-high tumor regions and a clonal PIK3CA mutation. panCK and MPO examples for CRUK0075:R2 illustrate the same region of interest, whereas different regions of interest are shown for CRUK0468:R6. Scale bar, 100 μm. P values for B and E were calculated in a linear mixed-effects model with patient as the random-effect covariate. P values in F and G were derived from a limma–voom differential expression analysis correcting for multiple regions per tumor. ·, P < 0.1; *, P < 0.05; **, P < 0.01; ***, P < 0.001; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TMM, trimmed mean of M-values; TS, tumor/stroma; TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; TAN, tumor-associated neutrophils; H&E, hematoxylin and eosin; mt, mutant; wt, wild-type.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Figure 6 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil infiltration is associated with recent subclonal expansion and poorer disease-free survival. A, Comparison of neutrophil cell density in primary tumors with metastasis-seeding clones detectable at time of surgery or during follow-up (metastasizing tumors) to tumors from patients who were metastasis-free and recurrence-free for more than 3 years of follow-up time (control) in LUAD (n = 28) and LUSC (n = 15) within the TRACERx discovery cohort. Maximum neutrophil density taken for tumors with multiple tumor cores. P values derived from one-tailed Wilcoxon test. B, Kaplan–Meier curves for DFS according to tumor-level TAN score in the validation cohort (n = 332 patients). P value derived from univariate Cox model adjusted for histology. C, Multivariable Cox proportional hazard regression analysis of DFS using tumor-level TAN score and tumor-level necrosis evaluation from H&E images of diagnostic tumor blocks. D, Recent subclonal expansion score, measured as the maximum cancer cell fraction of subclones at the terminus of the phylogenetic tree, compared between TAN-high and TAN-low tumor regions in LUAD and LUSC patients from the TRACERx 421 cohort. P values were derived from a linear mixed effects model with patient as random effect. E, Spatial ITH score of cell types and communities and ITH probabilities of TME classes in multiregion analysis (pan-immune n = 41 tumors, 112 cores). ITH score was calculated as the average standard deviation of the cell/community density in multiple regions per tumor and z-score transformed. ITH score of αSMA+ cells was derived from T cells and stroma panel (n = 39 tumors, 105 cores). ITH probability was calculated as 1 − probability of all regions having the same indicated TME class. F, Example phylogenetic tree depicting a stage IIIA LUSC case with a clonal PIK3CA mutation, high TAN scores, and recent subclonal expansion, including in a region (R5) that seeded a lymph node (LN) metastasis (FLN, FFPE LN). The metastasis-seeding lineage is highlighted in orange. Tumor-level TAN scores and regional subclonal expansion (SubExp) scores are reported for primary tumor regions. The reported TAN score represents the maximum of the tumor nest and stroma scores. Each cluster in the phylogenetic tree is assigned a color that is also represented in the region clone maps. The clone maps illustrate the prevalence of each clone within a region. G, IMC images shown for R5 and the LN metastasis. Scale bar, 200 μm. H, Summary schematic of the link between tumors with a neutrophil enriched microenvironment with tumor progression. ·, P < 0.1; *, P < 0.05; **, P < 0.01; ***, P < 0.001; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; ITH, intratumor heterogeneity.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil infiltration is associated with recent subclonal expansion and poorer disease-free survival. A, Comparison of neutrophil cell density in primary tumors with metastasis-seeding clones detectable at time of surgery or during follow-up (metastasizing tumors) to tumors from patients who were metastasis-free and recurrence-free for more than 3 years of follow-up time (control) in LUAD (n = 28) and LUSC (n = 15) within the TRACERx discovery cohort. Maximum neutrophil density taken for tumors with multiple tumor cores. P values derived from one-tailed Wilcoxon test. B, Kaplan–Meier curves for DFS according to tumor-level TAN score in the validation cohort (n = 332 patients). P value derived from univariate Cox model adjusted for histology. C, Multivariable Cox proportional hazard regression analysis of DFS using tumor-level TAN score and tumor-level necrosis evaluation from H&E images of diagnostic tumor blocks. D, Recent subclonal expansion score, measured as the maximum cancer cell fraction of subclones at the terminus of the phylogenetic tree, compared between TAN-high and TAN-low tumor regions in LUAD and LUSC patients from the TRACERx 421 cohort. P values were derived from a linear mixed effects model with patient as random effect. E, Spatial ITH score of cell types and communities and ITH probabilities of TME classes in multiregion analysis (pan-immune n = 41 tumors, 112 cores). ITH score was calculated as the average standard deviation of the cell/community density in multiple regions per tumor and z-score transformed. ITH score of αSMA+ cells was derived from T cells and stroma panel (n = 39 tumors, 105 cores). ITH probability was calculated as 1 − probability of all regions having the same indicated TME class. F, Example phylogenetic tree depicting a stage IIIA LUSC case with a clonal PIK3CA mutation, high TAN scores, and recent subclonal expansion, including in a region (R5) that seeded a lymph node (LN) metastasis (FLN, FFPE LN). The metastasis-seeding lineage is highlighted in orange. Tumor-level TAN scores and regional subclonal expansion (SubExp) scores are reported for primary tumor regions. The reported TAN score represents the maximum of the tumor nest and stroma scores. Each cluster in the phylogenetic tree is assigned a color that is also represented in the region clone maps. The clone maps illustrate the prevalence of each clone within a region. G, IMC images shown for R5 and the LN metastasis. Scale bar, 200 μm. H, Summary schematic of the link between tumors with a neutrophil enriched microenvironment with tumor progression. ·, P < 0.1; *, P < 0.05; **, P < 0.01; ***, P < 0.001; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; ITH, intratumor heterogeneity.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Supplementary Table S1. Imaging mass cytometry antibody panel information. Supplementary Table S2. TRACERx 100 imaging mass cytometry cohort information. Supplementary Table S3. TRACERx 421 cohort information. Supplementary Table S4. Median cell densities per histology, tissue type and TME class. Supplementary Table S5. Multivariable model of disease-free survival including TAN score, relevant clinical features together with PIK3CA mutation status (a) or recent subclonal expansion (b).
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Supplementary Table S1. Imaging mass cytometry antibody panel information. Supplementary Table S2. TRACERx 100 imaging mass cytometry cohort information. Supplementary Table S3. TRACERx 421 cohort information. Supplementary Table S4. Median cell densities per histology, tissue type and TME class. Supplementary Table S5. Multivariable model of disease-free survival including TAN score, relevant clinical features together with PIK3CA mutation status (a) or recent subclonal expansion (b).
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Figure 5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil-rich TMEs are associated with activating mutations in PI3K and tumor-intrinsic CXCL8 upregulation. A, Representative crops of tumor-level H&E images with low TAN scores in the tumor nest and stroma (left) and high TAN scores in the tumor nest and stroma (right), inferred as the proportion of the neutrophil area in tumor/stroma from the total tumor/stroma tissue area. Scale bar, 50 μm; 400× magnification. B, Neutrophil cell density as defined by IMC compared between region-level TAN-low versus TAN-high tumor cores based on H&E scores in LUAD and LUSC. C and D, Proportion of tumor cores with (mut) and without (wt) PIK3CA driver mutations compared between TS:Neutrophil high versus other TME classes combined (C) and region-level TAN-High versus TAN-Low cores (D) in LUSC. P values were derived from a Chi-square test. E, Neutrophil cell density by PIK3CA mutation status, points colored by TME class assignment. F and G, TMM expression values for CXCL8 compared by PIK3CA mutation status (F) and between TME classes (G) in LUSC. H, Immunofluorescence images of CXCL8 RNAscope multiplexed with antibody staining of pancytokeratin (panCK) or MPO in an LUSC tumor region with a TS:Neutrophil high TME and subclonal PIK3CA mutation, and an LUSC patient with multiple TAN-high tumor regions and a clonal PIK3CA mutation. panCK and MPO examples for CRUK0075:R2 illustrate the same region of interest, whereas different regions of interest are shown for CRUK0468:R6. Scale bar, 100 μm. P values for B and E were calculated in a linear mixed-effects model with patient as the random-effect covariate. P values in F and G were derived from a limma–voom differential expression analysis correcting for multiple regions per tumor. ·, P < 0.1; *, P < 0.05; **, P < 0.01; ***, P < 0.001; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TMM, trimmed mean of M-values; TS, tumor/stroma; TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; TAN, tumor-associated neutrophils; H&E, hematoxylin and eosin; mt, mutant; wt, wild-type.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil-rich TMEs are associated with activating mutations in PI3K and tumor-intrinsic CXCL8 upregulation. A, Representative crops of tumor-level H&E images with low TAN scores in the tumor nest and stroma (left) and high TAN scores in the tumor nest and stroma (right), inferred as the proportion of the neutrophil area in tumor/stroma from the total tumor/stroma tissue area. Scale bar, 50 μm; 400× magnification. B, Neutrophil cell density as defined by IMC compared between region-level TAN-low versus TAN-high tumor cores based on H&E scores in LUAD and LUSC. C and D, Proportion of tumor cores with (mut) and without (wt) PIK3CA driver mutations compared between TS:Neutrophil high versus other TME classes combined (C) and region-level TAN-High versus TAN-Low cores (D) in LUSC. P values were derived from a Chi-square test. E, Neutrophil cell density by PIK3CA mutation status, points colored by TME class assignment. F and G, TMM expression values for CXCL8 compared by PIK3CA mutation status (F) and between TME classes (G) in LUSC. H, Immunofluorescence images of CXCL8 RNAscope multiplexed with antibody staining of pancytokeratin (panCK) or MPO in an LUSC tumor region with a TS:Neutrophil high TME and subclonal PIK3CA mutation, and an LUSC patient with multiple TAN-high tumor regions and a clonal PIK3CA mutation. panCK and MPO examples for CRUK0075:R2 illustrate the same region of interest, whereas different regions of interest are shown for CRUK0468:R6. Scale bar, 100 μm. P values for B and E were calculated in a linear mixed-effects model with patient as the random-effect covariate. P values in F and G were derived from a limma–voom differential expression analysis correcting for multiple regions per tumor. ·, P < 0.1; *, P < 0.05; **, P < 0.01; ***, P < 0.001; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TMM, trimmed mean of M-values; TS, tumor/stroma; TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; TAN, tumor-associated neutrophils; H&E, hematoxylin and eosin; mt, mutant; wt, wild-type.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Figure 4 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil infiltration in LUSC is associated with distinct metabolic and immunosuppressive phenotypes. A, Gene Ontology (GO) biological processes enriched among upregulated genes in the TS:Neutrophil high TME class (n = 10 cores) compared with other TME classes combined (n = 28 cores) in LUSC (FDR < 0.01, gene ratio > 0.05). B, GSEA of hallmark gene sets compared between tumor cores from the Tumor/Stroma:Neutrophil high TME class and other TME classes combined, using the t-statistic derived from the limma–voom model on TMM-normalized gene expression. Significantly enriched pathways were colored by type of pathway (FDR < 0.05). C, Normalized enrichment score derived from single-sample GSEA visualized for TS:Neutrophil high and cores from other TME classes. The P value is derived from GSEA of LUSC as shown in A and adjusted for other hallmark pathways using the Benjamini–Hochberg method. D, Proportion of tumor cells assigned MCT4+ in TS:Neutrophil high tumor cores compared with tumor cores from other TME classes combined in LUSC. E, Spearman correlation coefficient and P value comparing the proportion of MCT4+ and CAIX+ tumor cells in TS:Neutrophil high LUSC TMEs. F, Median distance between LUSC tumor cells to their nearest endothelial cell per core in TS:Neutrophil high TME class compared with all other TME classes combined. G, Single-channel images and composite image alongside cell type map displaying tumor cells, neutrophils (MPO, yellow), endothelial cells (CD31, magenta), and regions of hypoxia (CAIX, cyan) and MCT4 (green) expression. Boxplots show median and lower and upper quartile values, and whiskers extend up to 1.5 × IQR above and below the quartiles. P values for D and F were calculated in a linear mixed-effects model with patient as the random-effect covariate. LUSC, lung squamous cell carcinoma; TS, tumor/stroma; FDR, false discovery rate; TMM, trimmed mean of M-values; panCK, pancytokeratin; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Neutrophil infiltration in LUSC is associated with distinct metabolic and immunosuppressive phenotypes. A, Gene Ontology (GO) biological processes enriched among upregulated genes in the TS:Neutrophil high TME class (n = 10 cores) compared with other TME classes combined (n = 28 cores) in LUSC (FDR < 0.01, gene ratio > 0.05). B, GSEA of hallmark gene sets compared between tumor cores from the Tumor/Stroma:Neutrophil high TME class and other TME classes combined, using the t-statistic derived from the limma–voom model on TMM-normalized gene expression. Significantly enriched pathways were colored by type of pathway (FDR < 0.05). C, Normalized enrichment score derived from single-sample GSEA visualized for TS:Neutrophil high and cores from other TME classes. The P value is derived from GSEA of LUSC as shown in A and adjusted for other hallmark pathways using the Benjamini–Hochberg method. D, Proportion of tumor cells assigned MCT4+ in TS:Neutrophil high tumor cores compared with tumor cores from other TME classes combined in LUSC. E, Spearman correlation coefficient and P value comparing the proportion of MCT4+ and CAIX+ tumor cells in TS:Neutrophil high LUSC TMEs. F, Median distance between LUSC tumor cells to their nearest endothelial cell per core in TS:Neutrophil high TME class compared with all other TME classes combined. G, Single-channel images and composite image alongside cell type map displaying tumor cells, neutrophils (MPO, yellow), endothelial cells (CD31, magenta), and regions of hypoxia (CAIX, cyan) and MCT4 (green) expression. Boxplots show median and lower and upper quartile values, and whiskers extend up to 1.5 × IQR above and below the quartiles. P values for D and F were calculated in a linear mixed-effects model with patient as the random-effect covariate. LUSC, lung squamous cell carcinoma; TS, tumor/stroma; FDR, false discovery rate; TMM, trimmed mean of M-values; panCK, pancytokeratin; *, P < 0.05; **, P < 0.01; ***, P < 0.001.